Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  bortezomib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 372 for your search:
Start Over
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C05004, NCT00257114
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003469, 26866138MMY4001, NCT00440765
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR012958, bortezomib PMS, NCT01005628
A Retreatment Study With Bortezomib for Multiple Myeloma
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR015814, 26866138MMY4039, BORKOR5021, NCT01030302
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR016750, BOR-KOR-5022, NCT01060202
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589DUS71, NCT01083602
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA200-003, KAG-302, NCT00514371
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Phase: Phase III, Phase II
Type: Diagnostic, Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: R08096M, 2008-003936-38, 26866138MMY2063, NCT00861250
Phase III Study of PS-341 in Patients With Refractory or Progressive Multiple Myeloma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MILLENNIUM-M34101-040, FHCRC-1747.00, NCI-G02-2128, NCT00049478
Phase III Randomized Study of Bortezomib Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MILLENNIUM-M34101-039, FHCRC-1746.00, NCI-G02-2130, NCT00048230
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2003-35, NCT00093028
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR004117, DOXILMMY3001, 2004-001842-34, NCT00103506
Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2005-01, NCT00111748
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT: 2005-001628-35, EBMT-CLWP: 42206611, NCT00256776
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: BRD 04/11-J, NCT00200681
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 26866138-MMY-3002, UCLA-0409110-01, JJPRD-26866138-MMY-3002, NCT00111319
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 61 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR006127, 26866138MMY3013, NCT00416208
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 0 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR006124, 26866138MMY3012, 2005-004948-31, NCT00416273
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 26866138-LYM-3001, NCT00312845
Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: NMSG 15/05, EudraCT No: 2005-002756-18, NCT00417911
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
Phase: Phase III
Type: Treatment
Status: Completed
Age: 66 and over
Sponsor: Other
Protocol IDs: 2005-001111-21, NCT00443235
GEM05 for Patients With Multiple Myeloma Under 65 Years
Phase: Phase III
Type: Treatment
Status: Completed
Age: 65 and under
Sponsor: Other
Protocol IDs: 2005-001110-41, NCT00461747
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C05009, NCT00507416
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00521, CDR0000561758, ECOG-E1A05, E1A05, U10CA021115, U10CA180820, NCT00522392
Start Over